Repligen RGEN · NASDAQ
$176.43 +0.58% (+$1.01)
Summary
37 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as free cash.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- Earnings per share fell by 36% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- It earns only 1.8 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 269.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it fell by 2.7% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share fell by 36% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 49 USD
- Research and development 7.0 USD
- Sales and administration 36 USD
- Taxes and other 3.0 USD
- Net profit 5.3 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 5.3 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 6.2 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 22
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $162.43 is 7.9% below today's price. 92% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 50%
- Filtration Products 27%
- Chromatography Products 10%
- Proteins Products 6.6%
- Process Analytics Products 5.5%
- Other 0.2%
By region
The company reports no revenue by region.
Product brings in 50% of revenue. Process Analytics Products grew fastest, by 14% a year.
Segments in detail